Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.
Cancer therapy
Panel gene sequencing
Precision oncology
Targeted therapy
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
25 Apr 2024
25 Apr 2024
Historique:
received:
27
11
2023
accepted:
15
04
2024
medline:
26
4
2024
pubmed:
26
4
2024
entrez:
25
4
2024
Statut:
epublish
Résumé
Panel gene sequencing is an established diagnostic tool for precision oncology of solid tumors, but its utility for the treatment of cancers of the digestive system in clinical routine is less well documented. We retrospectively identified patients with advanced or metastatic gastrointestinal, pancreaticobiliary or hepatic cancers who received panel gene sequencing at a tertiary university hospital from 2015 to 2022. For these cases, we determined the spectrum of genetic alterations, clinicopathological parameters and treatment courses. Assessment of actionability of genetic alterations was based on the OncoKB database, cancer-specific ESMO treatment guidelines, and recommendations of the local molecular tumor board. In total, 155 patients received panel gene sequencing using either the Oncomine Focus (62 cases), Comprehensive (91 cases) or Childhood Cancer Research Assay (2 cases). The mean age of patients was 61 years (range 24-90) and 37% were female. Most patients suffered from either colorectal cancer (53%) or cholangiocellular carcinoma (19%). 327 genetic alterations were discovered in 123 tumor samples, with an average number of 2.1 alterations per tumor. The most frequently altered genes were TP53, KRAS and PIK3CA. Actionable gene alterations were detected in 13.5-56.8% of tumors, according to ESMO guidelines or the OncoKB database, respectively. Thirteen patients were treated with targeted therapies based on identified molecular alterations, with a median progression-free survival of 8.8 months. Actionable genetic alterations are frequently detected by panel gene sequencing in patients with advanced cancers of the digestive tract, providing clinical benefit in selected cases. However, for the majority of identified actionable alterations, sufficient clinical evidence for targeted treatments is still lacking.
Sections du résumé
BACKGROUND
BACKGROUND
Panel gene sequencing is an established diagnostic tool for precision oncology of solid tumors, but its utility for the treatment of cancers of the digestive system in clinical routine is less well documented.
METHODS
METHODS
We retrospectively identified patients with advanced or metastatic gastrointestinal, pancreaticobiliary or hepatic cancers who received panel gene sequencing at a tertiary university hospital from 2015 to 2022. For these cases, we determined the spectrum of genetic alterations, clinicopathological parameters and treatment courses. Assessment of actionability of genetic alterations was based on the OncoKB database, cancer-specific ESMO treatment guidelines, and recommendations of the local molecular tumor board.
RESULTS
RESULTS
In total, 155 patients received panel gene sequencing using either the Oncomine Focus (62 cases), Comprehensive (91 cases) or Childhood Cancer Research Assay (2 cases). The mean age of patients was 61 years (range 24-90) and 37% were female. Most patients suffered from either colorectal cancer (53%) or cholangiocellular carcinoma (19%). 327 genetic alterations were discovered in 123 tumor samples, with an average number of 2.1 alterations per tumor. The most frequently altered genes were TP53, KRAS and PIK3CA. Actionable gene alterations were detected in 13.5-56.8% of tumors, according to ESMO guidelines or the OncoKB database, respectively. Thirteen patients were treated with targeted therapies based on identified molecular alterations, with a median progression-free survival of 8.8 months.
CONCLUSIONS
CONCLUSIONS
Actionable genetic alterations are frequently detected by panel gene sequencing in patients with advanced cancers of the digestive tract, providing clinical benefit in selected cases. However, for the majority of identified actionable alterations, sufficient clinical evidence for targeted treatments is still lacking.
Identifiants
pubmed: 38664720
doi: 10.1186/s12885-024-12261-2
pii: 10.1186/s12885-024-12261-2
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
526Informations de copyright
© 2024. The Author(s).
Références
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal Cancer. Gastroenterology. 2020;159:335–e34915.
doi: 10.1053/j.gastro.2020.02.068
pubmed: 32247694
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.
doi: 10.1038/nm.4333
pubmed: 28481359
pmcid: 5461196
Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci. 2019;110:1480–90.
doi: 10.1111/cas.13969
pubmed: 30742731
pmcid: 6447843
Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33:3817–25.
doi: 10.1200/JCO.2015.61.5997
pubmed: 26304871
pmcid: 4737863
Bregni G, Sticca T, Camera S, Akin Telli T, Craciun L, Trevisi E, et al. Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel. Acta Oncol (Madr). 2020;59:1438–46.
doi: 10.1080/0284186X.2020.1809704
Takeda H, Imoto K, Umemoto K, Doi A, Arai H, Horie Y, et al. Clinical utility of genomic profiling tests in patients with Advanced gastrointestinal cancers. Target Oncol. 2022;17:177–85.
doi: 10.1007/s11523-022-00871-4
pubmed: 35366174
Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (NCI-MATCH). J Clin Oncol. 2020;38:3883–94.
doi: 10.1200/JCO.19.03010
pubmed: 33048619
pmcid: 7676882
Morganti S, Tarantino P, Ferraro E, D’Amico P, Viale G, Trapani D, et al. Complexity of genome sequencing and reporting: next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol/Hematol. 2019;133:171–82.
doi: 10.1016/j.critrevonc.2018.11.008
pubmed: 30661654
Inagaki C, Maeda D, Hatake K, Sato Y, Hashimoto K, Sakai D, et al. Clinical utility of next-generation sequencing‐based panel testing under the universal health‐care system in Japan: a retrospective analysis at a single university hospital. Cancers (Basel). 2021;13:1–14.
doi: 10.3390/cancers13051121
Lamarca A, Kapacee Z, Breeze M, Bell C, Belcher D, Staiger H, et al. Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med. 2020;9:1–18.
doi: 10.3390/jcm9092854
Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, et al. Assessment of Clinical Benefit of Integrative genomic profiling in Advanced Solid tumors. JAMA Oncol. 2021;7:525–33.
pubmed: 33630025
Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, Proto C et al. Molecular Tumor Board as a clinical Tool for converting Molecular Data Into Real-World patient care. JCO Precis Oncol. 2023;7.
Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, et al. OncoKB: a Precision Oncology Knowledge Base. JCO Precis Oncol. 2017;2017:1–16.
doi: 10.1200/PO.17.00011
Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O’Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Ann Oncol. 2023. https://doi.org/10.1016/j.annonc.2023.08.009 .
doi: 10.1016/j.annonc.2023.08.009
pubmed: 37805130
Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:992–1004.
doi: 10.1016/j.annonc.2022.07.003
pubmed: 35914638
Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005–20.
doi: 10.1016/j.annonc.2022.07.004
pubmed: 35914639
Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238–55.
doi: 10.1093/annonc/mdy308
pubmed: 30285213
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Ann Oncol. 2023;34:10–32.
doi: 10.1016/j.annonc.2022.10.003
pubmed: 36307056
Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Ann Oncol. 2023;34:127–40.
doi: 10.1016/j.annonc.2022.10.506
pubmed: 36372281
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29:1895–902.
doi: 10.1093/annonc/mdy263
pubmed: 30137196
pmcid: 6158764
Lier A, Penzel R, Heining C, Horak P, Fröhlich M, Uhrig S, et al. Validating Comprehensive Next-Generation sequencing results for Precision Oncology: the NCT/DKTK molecularly aided stratification for Tumor Eradication Research Experience. JCO Precis Oncol. 2018;2:1–13.
doi: 10.1200/PO.18.00171
pubmed: 35135162
Groβ S, Bitzer M, Blödt S, Follmann M, Langer T, Freudenberger P, et al. Leitlinienreport Der S3-Leitlinie Diagnostik Und Therapie Des Hepatozellulären Karzinoms und biliärer Karzinome - Version 3.0 - Juli 2022, AWMF-Registernummer: 032/053OL. Z Gastroenterol. 2022;61:E157–71.
Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:773–81.
doi: 10.1016/S1470-2045(12)70270-X
pubmed: 22805291
Sacher A, LoRusso P, Patel MR, Miller WH, Garralda E, Forster MD, et al. Single-Agent Divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023;389:710–21.
doi: 10.1056/NEJMoa2303810
pubmed: 37611121
Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023;388:33–43.
doi: 10.1056/NEJMoa2208470
pubmed: 36546651
Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou S-HI, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;388:44–54.
doi: 10.1056/NEJMoa2212419
pubmed: 36546659
Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619:160–6.
doi: 10.1038/s41586-023-06123-3
pubmed: 37258666
pmcid: 10322706
Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet. 2017;49:170–4.
doi: 10.1038/ng.3774
pubmed: 28138153
pmcid: 5367263
Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 2018;10.
Patterson SE, Liu R, Statz CM, Durkin D, Lakshminarayana A, Mockus SM. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. Hum Genomics. 2016;10.
Welland S, DeCastro T, Bathon M, Wirth TC, Reineke-Plaaß T, Saborowski M, et al. Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience. J Cancer Res Clin Oncol. 2022;148:2137–44.
doi: 10.1007/s00432-021-03774-5
pubmed: 34436668
Dhir M, Choudry HA, Holtzman MP, Pingpank JF, Ahrendt SA, Zureikat AH, et al. Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies. Cancer Med. 2017;6:195–206.
doi: 10.1002/cam4.992
pubmed: 28028924
Agrawal L, Engel KB, Greytak SR, Moore HM. Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Sem Cancer Biol. 2018;52:26–38.
doi: 10.1016/j.semcancer.2017.12.008
von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPE samples. PLoS ONE. 2007;2.
André T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability–high Advanced Colorectal Cancer. N Engl J Med. 2020;383:2207–18.
doi: 10.1056/NEJMoa2017699
pubmed: 33264544
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796–807.
doi: 10.1016/S1470-2045(20)30157-1
pubmed: 32416072
pmcid: 7523268
Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019;381:1632–43.
doi: 10.1056/NEJMoa1908075
pubmed: 31566309
Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Overall survival results from the POLO trial: a phase III study of active maintenance Olaparib Versus Placebo for Germline BRCA-Mutated metastatic pancreatic Cancer. J Clin Oncol. 2022;40:3929–39.
doi: 10.1200/JCO.21.01604
pubmed: 35834777
pmcid: 10476841
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA -Mutated metastatic pancreatic Cancer. N Engl J Med. 2019;381:317–27.
doi: 10.1056/NEJMoa1903387
pubmed: 31157963
pmcid: 6810605
Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018;39:593–620.
doi: 10.1002/humu.23406
pubmed: 29446198
pmcid: 5903938
Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, et al. BRCA2 hypomorphic missense variants Confer moderate risks of breast Cancer. Cancer Res. 2017;77:2789–99.
doi: 10.1158/0008-5472.CAN-16-2568
pubmed: 28283652
pmcid: 5508554
Kiavue N, Cabel L, Melaabi S, Bataillon G, Callens C, Lerebours F, et al. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene. 2020;39:487–502.
doi: 10.1038/s41388-019-1001-5
pubmed: 31519989
Bidard FC, Ng CKY, Cottu P, Piscuoglio S, Escalup L, Sakr RA, et al. Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. Ann Oncol. 2015;26:1704–9.
doi: 10.1093/annonc/mdv217
pubmed: 25953157
Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23:603–17.
doi: 10.1016/j.ccr.2013.04.012
pubmed: 23680147